Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
26
07
2019
accepted:
19
01
2020
entrez:
5
5
2020
pubmed:
5
5
2020
medline:
5
5
2020
Statut:
epublish
Résumé
Inhaled corticosteroid/long-acting β
Identifiants
pubmed: 32363206
doi: 10.1183/23120541.00187-2019
pii: 00187-2019
pmc: PMC7184113
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©ERS 2020.
Déclaration de conflit d'intérêts
Conflict of interest: N.A. Hanania has received personal fees for serving on advisory boards or as a consultant for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mylan, Novartis, Sanofi Genzyme and Sunovion; his institution has received research grant support on his behalf from AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline. Conflict of interest: A. Papi reports board membership, consultancy, payment for lectures, grants for research and travel expenses reimbursement from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma and TEVA; payment for lectures and travel expenses reimbursement from Menarini, Novartis and Zambon; board membership, payment for lectures, grants for research and travel expenses reimbursement from Pfizer; and grants from Sanofi, outside the submitted work. Conflict of interest: A. Anzueto reports personal fees for consultancy from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Sunovion Pharmaceutical; and a research grant to University of Texas Health, San Antonio, from GlaxoSmithKline, outside the submitted work. Conflict of interest: F.J. Martinez reports personal fees, nonfinancial support and other from Boehringer Ingelheim during the conduct of the study; personal fees and nonfinancial support from the American College of Chest Physicians, AstraZeneca, Boehringer Ingelheim, Canadian Respiratory Network, Chiesi, ConCert, Continuing Education, Genentech, GlaxoSmithKline, Inova Fairfax Health System, Miller Communications, the National Association for Continuing Education, Novartis, Pearl Pharmaceuticals, PeerView Communications, Physicians Education Resource, Potomac, Prime Communications, the Puerto Rican Respiratory Society, Roche, Rockpointe, Sunovion, Teva, Theravance, Unity, University of Alabama Birmingham, UpToDate, WebMD/Medscape and the Western Connecticut Health Network; nonfinancial support from Gilead, Nitto, ProterixBio and Zambon; personal fees from Academic CME, the American Thoracic Society, Columbia University, Integritas, MD Magazine, Methodist Hospital Brooklyn, New York University, Patara, PlatformIQ; other from Afferent/Merck, Bayer, Biogen, Bridge Biotherapeutics, Prometic and Veracyte; grants from the NIH, Promedior and Rare Disease Healthcare Communications. Conflict of interest: K.A. Rossman is a full-time employee of AstraZeneca. Conflict of interest: C.S. Cappelletti is a full-time employee of AstraZeneca. Conflict of interest: E.A. Duncan is a full-time employee of AstraZeneca. Conflict of interest: J.S. Nyberg is a former employee of AstraZeneca. Conflict of interest: P.M. Dorinsky is a full-time employee of AstraZeneca.
Références
Lancet Respir Med. 2016 May;4(5):390-8
pubmed: 27066739
BMJ. 2013 May 29;346:f3306
pubmed: 23719639
Am J Respir Crit Care Med. 2007 Jul 15;176(2):162-6
pubmed: 17400730
Eur Respir J. 2003 Dec;22(6):912-9
pubmed: 14680078
Eur Respir J. 2003 Jan;21(1):74-81
pubmed: 12570112
Respir Med. 2019 Oct - Nov;158:59-66
pubmed: 31605923
Eur Respir J. 2017 Jun 22;49(6):
pubmed: 28642311
Am J Respir Crit Care Med. 1999 Jan;159(1):179-87
pubmed: 9872837
Eur Respir J. 2018 Sep 16;52(3):
pubmed: 30220648
COPD. 2009 Oct;6(5):320-9
pubmed: 19863361
Respir Med. 2017 Nov;132:31-41
pubmed: 29229103
Int J Chron Obstruct Pulmon Dis. 2017 Oct 19;12:3055-3064
pubmed: 29089754
Lancet Respir Med. 2015 Jun;3(6):435-42
pubmed: 25878028
Eur Respir J. 2018 Dec 13;52(6):
pubmed: 30545959
J Allergy Clin Immunol. 2018 Jun;141(6):2037-2047.e10
pubmed: 29709670
Respirology. 2013 Jul;18(5):866-73
pubmed: 23551359
Thorax. 2013 Nov;68(11):1029-36
pubmed: 24130228
N Engl J Med. 2007 Feb 22;356(8):775-89
pubmed: 17314337
Drugs. 2008;68(14):1975-2000
pubmed: 18778120
Int J Chron Obstruct Pulmon Dis. 2017 Apr 05;12:1071-1084
pubmed: 28435240
Drugs. 2009;69(5):549-65
pubmed: 19368417
Eur Respir J. 2004 Jun;23(6):932-46
pubmed: 15219010
Lancet. 2003 Feb 8;361(9356):449-56
pubmed: 12583942
Arch Bronconeumol. 2020 Feb;56(2):65-67
pubmed: 31320191
Lancet Respir Med. 2018 Oct;6(10):747-758
pubmed: 30232048
Am J Respir Crit Care Med. 2015 Aug 15;192(4):523-5
pubmed: 26051430
Lancet Respir Med. 2018 Feb;6(2):117-126
pubmed: 29331313
Respir Med. 2012 Feb;106(2):257-68
pubmed: 22033040
AAPS PharmSciTech. 2018 Feb;19(2):837-844
pubmed: 29019170
Langmuir. 2012 Oct 23;28(42):15015-23
pubmed: 22985189